Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Zavicefta: Additional Ph III REPROVE data

Additional data from the double-blind, double-dummy, international Phase III REPROVE trial in 879 patients with HAP, including VAP, showed that 2,000 mg/500 mg IV Zavicefta ceftazidime/avibactam as a 2-hour infusion every 8

Read the full 327 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers